Invicta Diagnostic IPO
Invicta Diagnostic IPO Details
-
Open Date
01 Dec 2025
-
Close Date
03 Dec 2025
-
Listing Date
08 Dec 2025
- IPO Price Range
₹ 80 to ₹85
- IPO Size
₹ 28.12 Cr
- Listing Exchange
NSE SME
Invicta Diagnostic IPO Timeline
Invicta Diagnostic IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 01-Dec-2025 | 0.00 | 0.68 | 0.29 | 0.54 |
| 02-Dec-2025 | 1.55 | 0.74 | 0.79 | 0.95 |
| 03-Dec-2025 | 3.51 | 6.96 | 3.44 | 4.27 |
Last Updated: 03 December 2025 6:15 PM by 5paisa
Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based provider of integrated radiology and pathology services. Operating a hub-and-spoke network across the Mumbai Metropolitan Region, it runs a central laboratory, seven diagnostic centres, and offers routine and specialised tests, including molecular diagnostics, advanced imaging such as CT and MRI, PET CT, and ultrasound. Its network of phlebotomists and collection points ensures convenient, wide-reaching sample collection.
Established in: 2021
Managing Director: Rohit Prakash Srivastava
Invicta Diagnostic Objectives
1. The company plans to allocate ₹21.11 crores towards acquiring medical equipment.
2. The company will use funds for general corporate purposes.
Invicta Diagnostic IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹28.12 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹28.12 Cr |
Invicta Diagnostic IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
| Retail (Min) | 2 | 3,200 | 2,56,00 |
| Retail (Max) | 2 | 3,200 | 2,72,000 |
| S - HNI (Min) | 3 | 4,800 | 3,84,000 |
| S - HNI (Max) | 7 | 11,200 | 9,52,000 |
| B - HNI (Max) | 8 | 12,800 | 10,24,000 |
Invicta Diagnostic IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 3.51 | 5,34,400 | 18,75,200 | 15.939 |
| Non-Institutional Buyers | 6.96 | 5,42,400 | 37,74,400 | 32.082 |
| bNII (bids above ₹10L) | 7.30 | 3,61,600 | 26,40,000 | 22.440 |
| sNII (bids below ₹10L) | 6.27 | 1,80,800 | 11,34,400 | 9.642 |
| Individual Investors (IND category bidding for 2 Lots) | 3.44 | 12,67,200 | 43,58,400 | 37.046 |
| Total** | 4.27 | 23,44,000 | 1,00,08,000 | 85.068 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 6.84 | 9.68 | 16.27 |
| EBITDA | 1.70 | 3.94 | 6.21 |
| Profit After Tax (PAT) | 0.24 | 4.01 | 5.23 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 5.66 | 11.10 | 17.46 |
| Share Capital | 5.04 | 0.13 | 8.42 |
| Total Liabilities | 0.56 | 1.04 | 2.19 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 1.70 | 3.31 | 2.79 |
| Net Cash Generated From / (used in) Investing Activities | -0.09 | -2.89 | -2.75 |
| Net Cash Generated From / (used in) Financing Activities | -1.92 | 0.42 | -0.12 |
| Net Increase / (Decrease) In Cash And Cash Equivalents | -0.31 | 0.84 | -0.08 |
Strengths
1. Extensive hub-and-spoke network across Mumbai region.
2. Wide range of pathology and radiology services.
3. Strong capability in advanced imaging technologies.
4. Efficient home and centre-based sample collection.
Weaknesses
1. Heavy reliance on regional market presence.
2. High capital costs for advanced equipment.
3. Limited national brand visibility beyond Mumbai.
4. Dependence on timely equipment upgrades and maintenance.
Opportunities
1. Rising demand for specialised diagnostic testing.
2. Expansion potential across neighbouring Indian states.
3. Increasing adoption of digital health reporting.
4. Scope to scale teleradiology service offerings.
Threats
1. Intense competition from large diagnostic chains.
2. Regulatory changes impacting pricing structures.
3. Rapid technology advancements requiring investment.
4. Economic slowdowns reducing discretionary health spending.
1. Expanding network supporting sustained revenue growth.
2. Strong demand for advanced diagnostic services.
3. Diversified portfolio reducing operational dependency.
4. Planned expansion enhancing future profitability potential.
Invicta Diagnostics operates within a rapidly expanding diagnostic services market driven by rising healthcare awareness, increasing demand for specialised tests, and improved access to advanced imaging. With its strong hub-and-spoke presence across Mumbai and a growing portfolio of routine and high-end diagnostics, the company is well-positioned to scale operations. Planned expansion through new centres and upgraded equipment further strengthens its long-term growth prospects.
- Companies
- Type
- Opening On
-
Wakefit Innovations
- Mainboard
- 08th Dec
- Pre-Book
-
Corona Remedies
- Mainboard
- 08th Dec
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Invicta Diagnostic IPO opens from December 1, 2025 to December 3, 2025.
The size of Invicta Diagnostic IPO is ₹28.12 Cr.
The price band of Invicta Diagnostic IPO is fixed at ₹80 to ₹85 per share.
To apply for Invicta Diagnostic IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Invicta Diagnostic IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Invicta Diagnostic IPO is of 3,200 shares and the investment required is ₹2,56,000.
The share allotment date of Invicta Diagnostic IPO is December 4, 2025
The Invicta Diagnostic IPO will likely be listed on December 8, 2025.
The book running lead managers for Invicta Diagnostic IPO is Socradamus Capital Pvt.Ltd.
Invicta Diagnostic IPO plans to utilise the raised capital from the IPO for:
1. The company plans to allocate ₹21.11 crores towards acquiring medical equipment.
2. The company will use funds for general corporate purposes.